Implications of MHRA's reclassification of tamsulosin.
Sheehan
William
W
Booth
Adam
A
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000145:classification*; D000368:Aged; D002387:Cataract Extraction; D003257:Consumer Product Safety / Q000331:legislation & jurisprudence; D017277:Drug Approval; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D006077:Government Agencies; D006801:Humans; D007431:Intraoperative Complications; D007499:Iris Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011680:Pupil / Q000187:drug effects; D013449:Sulfonamides / Q000145:classification*; D000077409:Tamsulosin; D006113:United Kingdom
D058668:Adrenergic alpha-1 Receptor Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin